Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8367591 | 0.99 | SIRT2 (0.55) | CTSLCTSSSIRT2SIRT1CTRB1 | |
| SCHEMBL27110955 | 0.90 | SYK (0.59) | CTSLCTSSSIRT2SIRT1CTRB1 | |
| SCHEMBL31191871 | 0.88 | SIRT2 (0.57) | CTSLCTSSSIRT2SIRT1CTRB1 | |
| SCHEMBL19050939 | 0.88 | CTSL (0.56) | CTSLCTSSSIRT2SIRT1CTRB1 | |
| SCHEMBL28563462 | 0.88 | SYK (0.58) | CTSLCTSSSIRT2SIRT1CTRB1 | |
| SCHEMBL27110953 | 0.87 | CTSL (0.55) | CTSLCTSSSIRT2SIRT1CTRB1 | |
| SCHEMBL17816595 | 0.87 | CTSL (0.55) | CTSLCTSSSIRT2SIRT1CTRB1 | |
| SCHEMBL19345761 | 0.87 | CTRB1 (0.53) | SIRT2SIRT1CTRB1SIRT3 | |
| SCHEMBL9574175 | 0.87 | CASP1 (0.60) | CTRB1SYK | |
| SCHEMBL7065592 | 0.86 | CTRB1 (0.50) | CTSLCTSSCTRB1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260177-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | US | disclosed |
| WO-2016089721-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260177-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | CTSL 4146/4885CTSS 3379/4885SIRT2 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.